Swedish-Nature-09-1248x672

iLite CDC Bioassays

Accurate Assessment of Antibody-Mediated Complement-Dependent Cytotoxicity

Assay-development-504x672

Accurate Assessment of Antibody-Mediated CDC

CDC Bioassays

Based on Svar’s proprietary iLite® technology, our Complement-Dependent Cytotoxicity (CDC) Bioassays offer a powerful tool for accurately measuring cell lysis in therapeutic antibody development.

iLite CDC Reporter Gene Assays

Our iLite assays streamline the assessment of antibody-mediated CDC, a crucial mechanism in immune responses and a common mechanism of action (MoA) for therapeutic antibodies.

  • A true measure of cell lysis, ideal for screening mAbs with CDC MoA
  • Uses the brilliant Svar LUC reporter-gene system for enhanced stability and precise quantification of cell death
  • "Assay-ready" format for rapid and convenient use
  • Easily adapted to other targets such as HER2, EGFR, mTNF, mVEGF, or your target of choice

Our CDC Reporter-Gene Assays

Didn't find what you were looking for?

We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.

iLite News

previous
Introducing the new iLite® C3a Assay Ready Cells

1 DECEMBER 2025

Introducing the new iLite® C3a Assay Ready Cells

Read post
Take advantage of a more comprehensive way of looking at AAV Immunogenicity – With a Partner Who Gets the full picture

6 AUGUST 2025

Take advantage of a more comprehensive way of looking at AAV Immunogenicity – With a Partner Who Get...

Read post
Introducing the AAV Complement Activation Assay: A New Standard in Safety Assessment for Gene Therapies

10 JULY 2025

Introducing the AAV Complement Activation Assay: A New Standard in Safety Assessment for Gene Therap...

Read post
Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection

2 JULY 2025

Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection

Read post
AAV Safety Assay Platform: The Immunogenicity Trifecta - NAb, TAb & Complement

30 JUNE 2025

AAV Safety Assay Platform: The Immunogenicity Trifecta - NAb, TAb & Complement

Read post
next

iLite Downloads

previous
Mechanism-linked potency assays drive Gene Therapy success

Editorial article

Mechanism-linked potency assays drive Gene Therapy success

Read post
Addressing the analytical gaps in modern therapeutic development

White Paper Application Story

Addressing the analytical gaps in modern therapeutic development

Read post
Partnering for success in advanced therapeutics

Partnering for success in advanced therapeutics

Read post
Case Study: How iLite® Technology Enhances Immunogenicity Testing

Case Story

Case Study: How iLite® Technology Enhances Immunogenicity Testing

Read post
Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated Gene Therapy

White Paper

Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated G...

Read post
next

20+
years of product development

All 3
complement pathways studied individually

<5h
assay time

265+
scientific paper references

Contact our iLite team

Write us a message and a complement specialist will get in touch